Talk about a love triangle. Actavis made an advance toward Allergan last month, which the latter spurned because it thought it was close to landing Salix. Now, sources tell CNBC that Actavis has swooped in on Salix, with deal talks ongoing.
A group of FDA advisers voted against recommending approval for a new combination blood-pressure treatment from Actavis, clouding the future of a prospect the company picked up in its $28 billion buyout of Forest Laboratories.
Usually exceeding expectations when it comes to a sales goal is a good thing. But in the case of Actavis and its forced switch of patients to a once-daily version of its Alzheimer's treatment Namenda, it is posing some problems--supply problems.
In an about-face, Forest Laboratories says it will continue to sell its original version of the Alzheimer's treatment Namenda into the fall of 2014, rather than taking it off the market in August.
For Actavis, the deal would deliver a new set of drugs for marketing, part of its core M&A strategy as Watson first snapped up Actavis, took the Swiss company's name and then engineered a $5 billion buyout of Warner Chilcott, gaining an Irish domicile and the considerable tax advantages that go with it.
With an eye to boosting its pipeline of experimental drugs for women's health, generics giant Watson Pharmaceuticals has swooped in and acquired Belgium's Uteron Pharma in a $305 million deal.
Step back and look at the trend in biopharma M&A and you'll find less money than you would have seen on the table last year. Read the report on this year's dealmaking climate >>
With a deal on the table to buy up a 51% stake in Poland's Bioton, Actavis says it wants to use the move as a springboard into biosimilars. Like a slate of biopharma companies, the Icelandic...
Iceland's generic drug maker Actavis has agreed to buy Abrika Pharmaceuticals in the U.S. for up to $238.5 million. Actavis will make an initial payment of $110 million in cash and up to $125 million based on its performance over the next three years. Actavis says the deal will make it a leader in the U.S. for controlled-release drugs. The Icelandic company recently lost a bidding war with Barr for Croatia's Pliva.- here's the …
Generic drug maker Actavis has announced that it has acquired a 51 percent controlling interest in Russian manufacturer ZiO Zdorovje. The total deal is for $60 million, and Actavis says that it hopes the investment will give it a foothold in the expanding Russian generics market. "We believe that the combination of our local manufacturing expertise with Actavis' extensive product portfolio will significantly enhance the growth prospects for both businesses and we are very excited …